(Press-News.org) An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.
The findings of FLINT, or the Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment Trial, were published online Nov. 6 in The Lancet. FLINT was sponsored by the NIH's National Institute of Diabetes and Digestive and Kidney Diseases.
"NASH is a common and potentially serious disease that currently has no approved treatment. Management typically includes weight loss through diet and exercise," said Averell Sherker, M.D., NIDDK program official for the NASH Clinical Research Network (NASH CRN), which performed the FLINT study.
Liver health improved in 45 percent of people on OCA versus 21 percent of the placebo group. "Although obeticholic acid did not eliminate liver disease in FLINT participants, it demonstrated a promising effect. Larger studies will be required to determine the drug's safety and efficacy," Sherker said.
FLINT enrolled 283 people at eight centers across the country. At the study's start, participants were 18 and older and had been diagnosed with definite or borderline NASH. They were randomly assigned to one of two groups: one took 25 milligrams of OCA daily and one received a placebo that resembled the OCA pill. The study was double-blinded, so neither participants nor investigators knew which person was in which group.
Trial investigators intended for the groups to receive the drug or placebo for 72 weeks, with an additional 24 weeks of follow-up off treatment. However, planned interim analysis for safety and efficacy showed that OCA had significant beneficial effects on NASH-related liver health.
The analysis also found unanticipated increases in total cholesterol in the OCA group. They had increased LDL cholesterol ("bad" cholesterol) and decreased HDL cholesterol ("good" cholesterol) - notable because NASH patients are already at higher risk for cardiovascular diseases. As cholesterol treatment was not standardized as part of the study, further research is needed to fully understand the potential effect of OCA on cholesterol.
Because of both factors, and with the concurrence of the Data Safety and Monitoring Board, NIDDK decided to stop treatment but continue the study, move all patients into the follow-up phase, and perform no additional liver biopsies - which carry their own risks. Adverse cholesterol increases were not sustained after stopping OCA.
"The FLINT trial represents an important advance in the search for treatments of NASH. The causes of NASH are not fully understood, and causes and treatments may be different among patients," said the study's lead author, Brent Neuschwander-Tetri, M.D., a professor at St. Louis University. "We need to study the changes in cholesterol levels more to know if the increases caused by obeticholic acid increase the risk of hardening of the arteries. We found that the improvement in liver enzymes with obeticholic acid were not sustained after treatment was stopped, so we would expect that treatment would need to be indefinite, much like the medications for diabetes and hypertension."
The major feature of NASH is fat in the liver, along with inflammation and damage. Over time, these may lead to loss of liver function, the need for liver transplantation and death. NASH may have no symptoms and can only be diagnosed with a liver biopsy. Beyond maintaining a healthy weight, people with NASH are advised to avoid alcohol and unnecessary medications. New cases of NASH have grown alongside the obesity epidemic. NASH is the third leading diagnosis requiring U.S. liver transplantation.
INFORMATION:
The FLINT trial (Clinical Trials No. NCT01265498) was supported by the NIDDK, National Cancer Institute and National Center for Advancing Translational Sciences, all part of NIH. Intercept Pharmaceuticals, Inc. provided partial funding and supplies.
The NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans. For more information about the NIDDK and its programs, see http://www.niddk.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH...Turning Discovery Into Health ®
New drug for common liver disease improves liver health
2014-11-07
ELSE PRESS RELEASES FROM THIS DATE:
NASA's hubble surveys debris-strewn exoplanetary construction yards
2014-11-07
Astronomers using NASA's Hubble Space Telescope have completed the largest and most sensitive visible-light imaging survey of dusty debris disks around other stars. These dusty disks, likely created by collisions between leftover objects from planet formation, were imaged around stars as young as 10 million years old and as mature as more than 1 billion years old.
"It's like looking back in time to see the kinds of destructive events that once routinely happened in our solar system after the planets formed," said survey leader Glenn Schneider of the University of Arizona's ...
Olaparib shows success in tumor response rate for patients with BRCA-related cancers
2014-11-06
Philadelphia - Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania. The positive response provides new hope for patients with ovarian, breast, pancreatic and prostate cancers whose conditions have not responded to standard therapies. Results of the phase II study are available online in the current issue of the Journal of Clinical Oncology.
For ...
Maize analysis yields whole new world of genetic science
2014-11-06
TALLAHASSEE, Fla. -- A groundbreaking paper from a team of Florida State University biologists could lead to a better understanding of how plants could adapt to and survive environmental swings such as droughts or floods.
The research, published in the latest issue of the journal The Plant Cell, sheds light on how chromatin (the complex of DNA and proteins) is organized in a cell and how plants regulate genetic material, so that some genes are turned on and others are turned off.
"If you understand how plants regulate their genetic material, you can possibly manipulate ...
Moving calves, managing stress
2014-11-06
Humane transport of livestock is important for both carcass quality and animal welfare. However, it is difficult to mitigate stress for animals in-transit. During a typical journey, calves lose weight due to the stress of weaning and being withdrawn from feed and water during transport. Many factors contribute to this stress, including welfare of the calves before transportation, and temperature and space allowance inside the trailer during transportation. A better understanding of the pre- and post-transportation risk factors and in-transit factors that influence calf ...
Grocery byproduct proves effective as energy supplement in cattle
2014-11-06
Food waste has become a serious problem in the United States and other countries. Approximately 34 million tons of food waste is deposited in landfills each year in the United States alone (EPA, 2014). The U.S. Environmental Protection Agency has recognized the use of food waste as animal feed as one of the best means to add value to food waste, while reducing landfill costs and greenhouse gas emissions, and at the same time improving food security.
In an article published in the November 2014 issue of the Journal of Animal Science ("Nutritional value of ensiled grocery ...
Using wheat as an energy source for beef cattle
2014-11-06
Wheat, along with corn and barley, is one of the three major feed grains used in North America. Most of the feed-class wheat is fed to poultry and swine. Beef producers are reluctant to use large quantities of wheat in diets of feedlot cattle because wheat ferments considerably more rapidly in the rumen than corn or barley and increases the risk of ruminal acidosis, which can compromise the health, wellbeing, and productivity of cattle.
In a study published in the November 2014 issue of the Journal of Animal Science ("Impact of hard vs. soft wheat and monensin level on ...
Of dragonflies and dinosaurs: Rutgers researcher helps map insect origins, evolution
2014-11-06
When the dinosaurs ruled the earth, they were already bugged by creatures who had gotten there many millions of years earlier: Dragonflies and damselflies. In fact, says Rutgers University-Newark biologist, Dr. Jessica Ware, the first creatures to take to the skies of earth did so 406 million years ago.
Ware knows of what she speaks: She is part of an international team of 100 researchers that just finished an unprecedented two-year project to map the evolution of insects using a molecular data set of unparalleled quality and dimensions. The initial report on their ...
Migration negation
2014-11-06
Most cancer deaths occur because of metastasis, yet progress in preventing and treating migratory cancer cells has been slow.
"It's been particularly challenging to design drugs that work against metastasis," said Taran Gujral, research fellow in systems biology at Harvard Medical School.
"Unfortunately, many cancers aren't detected until after they've already metastasized."
Gujral and colleagues have now identified a cellular culprit that should help researchers better understand how metastasis begins. Their findings may also inform the design of new treatments ...
Study shows integrative medicine relieves pain and anxiety for cancer inpatients
2014-11-06
Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health care providers.
The Penny George Institute for Health and Healing researchers found that integrative medicine therapies can substantially decrease pain and anxiety for hospitalized cancer patients. Their findings are published in the current issue of the Journal of the National Cancer Institute Monographs.
"Following Integrative medicine interventions, such as medical massage, acupuncture, guided imagery or relaxation response ...
Greater use of social media gets science, scientists noticed, study says
2014-11-06
MADISON, Wis. -- Here is an idea worth following: "share" for tenure; "like" to get cited.
Academic researchers are turning to social media more and more, according to Dominique Brossard, and not just to post family photos or crack wise via hashtag.
"I've been in science communication for a while now, and I am really seeing a change -- especially among the younger scientists -- in their willingness to share their work," says Brossard, a University of Wisconsin-Madison professor of life sciences communication.
It's the venue for that sharing that has inspired work ...